Tuberous sclerosis complex: neurological, renal and pulmonary manifestations
- PMID: 21210335
- PMCID: PMC4629839
- DOI: 10.1055/s-0030-1269906
Tuberous sclerosis complex: neurological, renal and pulmonary manifestations
Abstract
Tuberous sclerosis complex (TSC) is an important cause of epilepsy and autism, as well as renal and pulmonary disease in adults and children. Affected individuals are subject to hamartomas in various organ systems which result from constitutive activation of the protein kinase mTOR (mammalian target of rapamycin). The clinical course, prognosis and appropriate therapy for TSC patients are often different from that for individuals with epilepsy, renal tumors, or interstitial lung disease, from other causes. Additionally, TSC serves as a model for other conditions in which the mTOR pathways are also up-regulated. This article reviews the molecular pathophysiology and management of neurological, renal and pulmonary manifestations of the disorder. The use of mTOR inhibitors such as rapamycin and everolimus is discussed and recent clinical trials of these drugs in TSC are reviewed.
© Georg Thieme Verlag KG Stuttgart · New York.
Figures
References
-
- Al-Saleem T, et al. Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer. 1998;83:2208–2216. - PubMed
-
- Augustine J, Bodziak K, Hricik D. Use of sirolimus in solid organ transplantation. Drugs. 2007;67:369–391. - PubMed
-
- Bernstein J, Meyer R. In: Parenchymal maldevelopment of the kidney in Brennemann-Kelley Practice of Pediatrics. KeHey V, editor. Harper; New York: 1967. pp. 1–30.
-
- Bernstein J, Robbins TO. Renal involvement in tuberous sclerosis. Ann N Y Acad Sci. 1991;615:36–49. - PubMed
-
- Bernstein J. Glomerulocystic kidney disease–nosological considerations. Pediatr Nephrol. 1993;7:464–470. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
